|
1
|
Molina R, Jo J, Filella X, Zanon G, Pahisa
J, Mu noz M, Farrus B, Latre ML, Escriche C, Estape J and Ballesta
AM: c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast
cancer: Prognostic value. Breast Cancer Res Treat. 51:109–119.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Berry DA, Cirrincione C, Henderson IC,
Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB,
Norton L, et al: Estrogen-receptor status and outcomes of modern
chemotherapy for patients with node-positive breast cancer. JAMA.
295:1658–1667. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bast RC Jr, Ravdin P, Hayes DF, Bates S,
Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG,
Somerfield MR, et al: 2000 Update of recommendations for the use of
tumor markers in breast and colorectal cancer: Clinical practice
guidelines of the American society of clinical oncology. J Clin
Oncol. 19:1865–1878. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Penault-Llorca F, André F, Sagan C,
Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC,
Bibeau F, Antoine M, et al: Ki67 expression and docetaxel efficacy
in patients with estrogen receptor-positive breast cancer. J Clin
Oncol. 27:2809–2815. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yarden Y: The EGFR family and its ligands
in human cancer. Signalling mechanisms and therapeutic
opportunities. Eur J Cancer. 37 (Suppl 4):S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sjögren S, Inganäs M, Lindgren A, Holmberg
L and Bergh J: Prognostic and predictive value of c-erbB-2
overexpression in primary breast cancer, alone and in combination
with other prognostic markers. J Clin Oncol. 16:462–469. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gabos Z, Sinha R, Hanson J, Chauhan N,
Hugh J, Mackey JR and Abdulkarim B: Prognostic significance of
human epidermal growth factor receptor positivity for the
development of brain metastasis after newly diagnosed breast
cancer. J Clin Oncol. 24:5658–5663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vogel CL, Cobleigh MA, Tripathy D, Gutheil
JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF,
Burchmore M, et al: Efficacy and safety of trastuzumab as a single
agent in first-line treatment of HER2-overexpressing metastatic
breast cancer. J Clin Oncol. 20:719–726. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roche PC and Ingle JN: Increased HER2 with
U.S. food and drug administration-approved antibody. J Clin Oncol.
17:4341999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Slamon D, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dawood S, Broglio K, Buzdar AU, Hortobagyi
GN and Giordano SH: Prognosis of women with metastatic breast
cancer by HER2 status and trastuzumab treatment: An
institutional-based review. J Clin Oncol. 28:92–98. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sundquist M, Brudin L and Tejler G:
Improved survival in metastatic breast cancer 1985–2016. Breast.
31:46–50. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smith I, Procter M, Gelber RD, Guillaume
S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G,
Baselga J, et al: 2-Year follow-up of trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer: A randomised
controlled trial. Lancet. 369:29–36. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, et al: Trastuzumab plus adjuvant chemotherapy for operable
HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schadendorf D, Hodi FS, Robert C, Weber
JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM and Wolchok JD:
Pooled analysis of long-term survival data from phase II and phase
III trials of ipilimumab in unresectable or metastatic melanoma. J
Clin Oncol. 33:1889–1894. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu
WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al:
Safety and tumor responses with lambrolizumab (anti-PD-1) in
melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rosenberg JE, Hoffman-Censits J, Powles T,
van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH,
Balmanoukian A, Loriot Y, et al: Atezolizumab in patients with
locally advanced and metastatic urothelial carcinoma who have
progressed following treatment with platinum-based chemotherapy: A
single-arm, multicentre, phase 2 trial. Lancet. 387:1909–1920.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fehrenbacher L, Spira A, Ballinger M,
Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D,
Artal-Cortes A, Lewanski C, et al: Atezolizumab versus docetaxel
for patients with previously treated non-small-cell lung cancer
(POPLAR): A multicentre, open-label, phase 2 randomised controlled
trial. Lancet. 387:1837–1846. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Loi S, Adams S, Schmid P, Cortes J, Cescon
DW, Winer EP, Toppmeyer DL, Rugo HS, De Laurentiis M, Nanda R, et
al: Relationship between tumor infiltrating lymphocyte (TIL) levels
and response to pembrolizumab (pembro) in metastatic
triple-negative breast cancer (mTNBC): Results from KEYNOTE-086.
Ann Oncol. 28 (Suppl 5):v6082017. View Article : Google Scholar
|
|
25
|
AlHarbi M, Ali Mobark N, AlMubarak L,
Aljelaify R, AlSaeed M, Almutairi A, Alqubaishi F, Hussain ME,
Balbaid AAO, Said Marie A, et al: Durable response to nivolumab in
a pediatric patient with refractory glioblastoma and constitutional
biallelic mismatch repair deficiency. Oncologist. 23:1401–1406.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ,
Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill
A, et al: Durable clinical benefit with nivolumab plus ipilimumab
in DNA mismatch repair-deficient/microsatellite instability-high
metastatic colorectal cancer. J Clin Oncol. 36:773–779. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fremda C, Hlevnjakb M, Zapatkab M, Zoernig
I, Halamaa N, Fejzibegovica N, Thewesb V, Lichterb P, Schirmacherc
P, Kloorc M, et al: Mismatch repair deficiency drives durable
complete remission by targeting programmed death receptor 1 in a
metastatic luminal breast cancer patient. Breast Care (Basel).
14:53–59. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bates JP, Derakhshandeh R, Jones L and
Webb TJ: Mechanisms of immune evasion in breast cancer. BMC Cancer.
18:5562018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rugo HS, Delord JP, Im SA, Ott PA,
Piha-Paul SA, Bedard PL, Sachdev J, Tourneau CL, van Brummelen EMJ,
Varga A, et al: Safety and antitumor activity of pembrolizumab in
patients with estrogen receptor-positive/human epidermal growth
factor receptor 2-negative advanced breast cancer. Clin Cancer Res.
24:2804–2811. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zacharakis N, Huq LM, Seitter SJ, Kim SP,
Gartner JJ, Sindiri S, Hill VK, Li YF, Paria BC, Ray S, et al:
Breast cancers are immunogenic: Immunologic analyses and a phase II
pilot clinical trial using mutation-reactive autologous
lymphocytes. J Clin Oncol. 40:1741–1754. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hoda RS, Brogi E, Dos Anjos CH,
Grabenstetter A, Ventura K, Patil S, Selenica P, Weigelt B,
Reis-Filho JS, Traina T, et al: Clinical and pathologic features
associated with PD-L1 (SP142) expression in stromal
tumor-infiltrating immune cells of triple-negative breast
carcinoma. Mod Pathol. 33:2221–2232. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Emens LA, Cruz C, Eder JP, Braiteh F,
Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, et
al: Long-term clinical outcomes and biomarker analyses of
atezolizumab therapy for patients with metastatic triple-negative
breast cancer: A phase 1 study. JAMA Oncol. 5:74–82. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nanda R, Chow LQ, Dees EC, Berger R, Gupta
S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al:
Pembrolizumab in patients with advanced triple-negative breast
cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol. 34:2460–2467.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Emens LA, Kok M and Ojalvo LS: Targeting
the programmed cell death-1 pathway in breast and ovarian cancer.
Curr Opin Obstet Gynecol. 28:142–147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schmid P, Adams S, Rugo HS, Schneeweiss A,
Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, et al:
Atezolizumab and Nab-paclitaxel in advanced triple-negative breast
cancer. N Engl J Med. 379:2108–2121. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cortes J, Cescon DW, Rugo HS, Nowecki Z,
Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et
al: Pembrolizumab plus chemotherapy versus placebo plus
chemotherapy for previously untreated locally recurrent inoperable
or metastatic triple-negative breast cancer (KEYNOTE-355): A
randomised, placebo-controlled, double-blind, phase 3 clinical
trial. Lancet. 396:1817–1828. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mittendorf EA, Philips AV, Meric-Bernstam
F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM,
Akcakanat A, et al: PD-L1 expression in triple-negative breast
cancer. Cancer Immunol Res. 2:361–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schalper KA, Velcheti V, Carvajal D,
Wimberly H, Brown J, Pusztai L and Rimm DL: In situ tumor PD-L1
mRNA expression is associated with increased TILs and better
outcome in breast carcinomas. Clin Cancer Res. 20:2773–2782. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Baptista MZ, Sarian LO, Derchain SF, Pinto
GA and Vassallo J: Prognostic significance of PD-L1 and PD-L2 in
breast cancer. Hum Pathol. 47:78–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sabatier R, Finetti P, Mamessier E,
Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D and
Bertucci F: Prognostic and predictive value of PDL1 expression in
breast cancer. Oncotarget. 6:5449–5464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bae SB, Cho HD, Oh MH, Lee JH, Jang SH,
Hong SA, Cho J, Kim SY, Han SW, Lee JE, et al: Expression of
programmed death receptor ligand 1 with high tumor-infiltrating
lymphocytes is associated with better prognosis in breast cancer. J
Breast Cancer. 19:242–251. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mahmoud SMA, Paish EC, Powe DG, Macmillan
RD, Grainge MJ, Lee AHS, Ellis IO and Green AR: Tumor-infiltrating
CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin
Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Muenst S, Schaerli AR, Gao F, Däster S,
Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE,
et al: Expression of programmed death ligand 1 (PD-L1) is
associated with poor prognosis in human breast cancer. Breast
Cancer Res Treat. 146:15–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li Z, Dong P, Ren M, Song Y, Qian X, Yang
Y, Li S, Zhang X and Liu F: PD-L1 expression is associated with
tumor FOXP3(+) regulatory T-cell infiltration of breast cancer and
poor prognosis of patient. J Cancer. 7:784–793. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Qin T, Zeng Y, Qin G, Xu F, Lu JB, Fang
WF, Xue C, Zhan JH, Zhang XK, Zheng QF, et al: High PD-L1
expression was associated with poor prognosis in 870 Chinese
patients with breast cancer. Oncotarget. 6:33972–33981. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Madjd Z, Spendlove I, Pinder SE, Ellis IO
and Durrant LG: Total loss of MHC class I is an independent
indicator of good prognosis in breast cancer. Int J Cancer.
117:248–255. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gudmundsdóttir I, Gunnlaugur Jónasson J,
Sigurdsson H, Olafsdóttir K, Tryggvadóttir L and Ogmundsdóttir HM:
Altered expression of HLA class I antigens in breast cancer:
Association with prognosis. Int J Cancer. 89:500–505. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zitvogel L, Tesniere A and Kroemer G:
Cancer despite immunosurveillance: Immunoselection and
immunosubversion. Nat Rev Immunol. 6:715–727. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Savas P, Salgado R, Denkert C, Sotinou C,
Darcy PK, Smyth MJ and Loi S: Clinical relevance of host immunity
in breast cancer: From TILs to the clinic. Nat Rev Clin Oncol.
13:228–241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Davies H, Morganella S, Purdie CA, Jang
SJ, Borgen E, Russnes H, Glodzik D, Zou X, Viari A, Richardson AL,
et al: Whole-genome sequencing reveals breast cancers with mismatch
repair deficiency. Cancer Res. 77:4755–4762. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Denkert C, von Mincwitz G, Darb-Esfahni S,
Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F,
Furlanetto J, et al: Tumour-infiltrating lymphocytes and prognosis
in different subtypes of breast cancer: A pooled analysis of 3771
patients treated with neoadjuvant therapy. Lancet Oncol. 19:40–50.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Denkert C, Wienert S, Poterie A, Loibl S,
Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, et
al: Standardized evaluation of tumor-infiltrating lymphocytes in
breast cancer: Results of the ring studies of the international
immuno-oncology biomarker working group. Mod Pathol. 29:1155–1164.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL,
Penault-Llorca F, et al: The evaluation of tumor-infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
international TILs working group 2014. Ann Oncol. 26:259–271. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Loi S, Michiels S, Adams S, Loibl S,
Budczies J, Denkert C and Salgado R: The journey of
tumor-infiltrating lymphocytes as a biomarker in breast cancer:
Clinical utility in an era of checkpoint inhibition. Ann Oncol.
32:1236–1244. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Igarashi T, Teramoto K, Ishida M, Hanaoka
J and Daigo Y: Scoring of PD-L1 expression intensity on pulmonary
adenocarcinomas and the correlations with clinicopathological
factors. ESMO Open. 1:e0000832016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Brookmeyer R and Crowley J: A k-sample
median test for censored data. J Am Stat Assoc. 77:433–440. 1982.
View Article : Google Scholar
|
|
58
|
Wen ZF, Liu H, Gao R, Zhou M, Ma J, Zhang
Y, Zhao J, Chen Y, Zhang T, Huang F, et al: Tumor cell-released
autophagosomes (TRAPs) promote immunosuppression through induction
of M2-like macrophages with increased expression of PD-L1. J
Immunother Cancer. 6:1512018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Vitale I, Manic G, Coussens LM, Kroemer G
and Galluzzi L: Macrophages and metabolism in the tumor
microenvironment. Cell Metab. 30:36–50. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Drake CG, Jaffee E and Pardoll DM:
Mechanisms of immune evasion by tumors. Adv Immunol. 90:51–81.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mamessier E, Sylvain A, Thibult ML,
Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P,
Romagné F, Thibault G, et al: Human breast cancer cells enhance
self tolerance by promoting evasion from NK cell antitumor
immunity. J Clin Invest. 121:3609–3622. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kim R, Emi M and Tanabe K: Cancer
immunoediting from immune surveillance to immune escape.
Immunology. 121:1–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Fang Y, Wang L, Wan C, Sun Y, Van der
Jeught K, Zhou Z, Dong T, So KM, Yu T, Li Y, et al: MAL2 drives
immune evasion in breast cancer by suppressing tumor antigen
presentation. Clin Invest. 131:e1408372021. View Article : Google Scholar
|
|
65
|
Spranger S and Gajewski TF: Impact of
oncogenic pathways on evasion of antitumour immune responses. Nat
Rev Cancer. 18:139–147. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Loi S, Sirtaine N, Piette F, Salgado R,
Viale G, Van Eenoo F, Rouas G, Francis P, Crown JPA, Hitre E, et
al: Prognostic and predictive value of tumor-infiltrating
lymphocytes in a phase III randomized adjuvant breast cancer trial
in node-positive breast cancer comparing the addition of docetaxel
to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J
Clin Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang N, Sun H, Zhao S, Wang Y, Pu H, Wang
Y and Zhang Q: Expression of PD-L1 and prognosis in breast cancer:
A meta-analysis. Oncotarget. 8:31347–31354. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Igarashi T, Teramoto K, Ishida M, Hanaoka
J and Daigo Y: The mechanism of de novo expression of programmed
cell death-ligand 1 in squamous cell carcinoma of the lung. Oncol
Rep. 38:2189–2196. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Teramoto K, Igarashi T, Kataoka Y, Ishida
M, Hanaoka J, Sumimoto H and Daigo Y: Biphasic prognostic
significance of PD-L1 expression status in patients with early- and
locally advanced-stage non-small cell lung cancer. Cancer Immunol
Immunother. 70:1063–1074. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Smith J, Robida MD, Acosta K, Vennapusa B,
Mistry A, Martin G, Yates A and Hnatyszyn HJ: Quantitative and
qualitative characterization of two PD-L1 clones: SP263 and E1L3N.
Diag Pathol. 11:442016. View Article : Google Scholar
|
